Drawing for CELGENE GLOBAL HEALTH

USPTO serial 85101797

CELGENE GLOBAL HEALTH

Reviewed by CopyMark Law Group

Reg. 3931147Status 710
Filing date
Status date
Registration date
Mar 15, 2011
Examiner
JENKINS JR, CHARLES L
Law office
TMEG LAW OFFICE 105

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with CELGENE GLOBAL HEALTH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Camille M. Miller

Camille M. Miller COZEN O'CONNOR, PC1650 Market StreetSuite 2800PHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
036[ Charitable fund raising services, namely, by providing individuals with the information and opportunity to make monetary donations to their favorite charity; charitable foundation services, namely, providing fund raising activities to support medical research and procedures for those in need; charitable fund raising services for sending underprivileged children to one of several camps around the United States which accept these children at discounted rates for one or more weeks; charitable fund raising services by means of an entertainment event; charitable fund raising services, namely, eleemosynary services in the field of collection, management, and disbursements of money in connection with programs and facilities for the welfare of children; financial services, namely, business fund raising provided over a computer network such as the Internet; charitable services, namely, providing financial assistance to patients and their families, charitable services, namely, providing funding to health care facilities and foundations for patients, charitable fund raising services; providing project grants for environmental and health awareness projects; charitable services, namely, providing financial support to disadvantaged patients for the purpose of facilitating good health ]SECTION 8 - CANCELLEDApr 14, 2010
041[ Education services, namely, providing mentoring, tutoring, classes, seminars, and workshops in the fields of highlighting the advancements made in cancer treatments and discussing the importance of continuing research to develop innovative new treatments ]SECTION 8 - CANCELLEDApr 14, 2010
042Development and testing services in the fields of biotechnology, chemistry and pharmaceuticals; [ providing an interactive web site that enables users to enter, access, track, monitor and generate health and medical information and reports; ] scientific study and research in the fields of the prevention, treatment and management of illness, health care delivery and the scientific aspects of health care policy, health care cost management and financing as these fields impact on quality of health care; research in the fields of chemicals and pharmaceuticals; research and testing services in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; providing clinical laboratory testing services, namely, pharmacogenetic tests, predictive medical tests, personalized medical tests, gene sequencing-based tests and genotyping based on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries; scientific research services; scientific research, namely, development of pharmaceuticals or diagnostic methods for othersSECTION 8 - CANCELLEDApr 14, 2010
044[ Providing links to web sites of others featuring information about the diagnosis and treatment of cancer; providing on-line information in the field of diagnosis and treatment of cancer; providing an on-line computer database featuring information relating to diagnosis and treatment of cancer; providing medical and pharmaceutical information services ]SECTION 8 - CANCELLEDApr 14, 2010

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 27, 2021NCS8NOTICE OF CANCELLATION SEC. 8 EMAILED—
Oct 26, 2021C8.TCANCELLED SEC. 8 (10-YR)—
Oct 16, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 15, 2020PR89POST REGISTRATION ACTION MAILED - SEC. 8 & 9—
May 11, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 16, 2020E89RTEAS SECTION 8 & 9 RECEIVED—
Mar 15, 2020REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
May 25, 2016NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
May 25, 2016C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
May 24, 2016APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 15, 2016E815TEAS SECTION 8 & 15 RECEIVED—
Mar 15, 2016REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 28, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 15, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 28, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 28, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 24, 2010PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 18, 2010ALIEASSIGNED TO LIE—
Nov 2, 2010CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 6, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 5, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 5, 2010TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 4, 2010GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 4, 2010GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 4, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 27, 2010DOCKASSIGNED TO EXAMINER—
Aug 12, 2010MDSCNOTICE OF DESIGN SEARCH CODE MAILED—
Aug 11, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 10, 2010NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance